Stock Abbreviation: Staidson
Stock Code: 300204
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Issuance Report for Issuance of Shares to Specific Targets
Sponsor (Lead Underwriter): Sinolink Securities Co., Ltd.
(No. 95 Dongcheng Gen Shangjie, Qingyang District, Chengdu)
July 2026
Declaration by the Issuer and All Directors, Audit Committee Members, and Senior Management
All directors, audit committee members, and senior management of the company hereby undertake that this Issuance Report contains no false records, misleading statements, or material omissions, and they shall bear individual and joint legal responsibility for the authenticity, accuracy, and completeness of the information contained herein.
Signatures of all company directors:
Zhou Zhiwen: [blank]
Zhang Rongqin: [blank]
Yang Lianchun: [blank]
Zhang Hongshan: [blank]
Zheng Hong: [blank]
Wang Xiaoyan: [blank]
Zhao Jiajun: [blank]
Zhai Yonggong: [blank]
Lu Qishun: [blank]
Date: [blank]
Signatures of all members of the Board Audit Committee:
Signatures of all senior management of the company:
Wang Chao: [blank]
Yu Maorong: [blank]
Li Shicheng: [blank]
Bai Xuelian: [blank]
Wang Jingfeng: [blank]
Zhang Lei: [blank]
Tian Lei: [blank]
Liu Xiaoning: [blank]
Table of Contents
Table of Contents ..........................................................................................................................5
Definitions ..........................................................................................................................6
Section I Basic Information on This Issuance ....................................................................................7
-
Relevant procedures performed for this issuance............................................................................7
-
Basic information on this issuance........................................................................................9
-
Basic information on the targets of this issuance..............................................................................15
-
Relevant institutions for this issuance..................................................................................21
Section II Comparison of Relevant Conditions Before and After the Issuance ..............................................................................24
-
Top ten shareholders before and after this issuance..................................................................24
-
Changes in shareholding of directors and senior management..........................................................25
-
Impact of this issuance on the company..............................................................................25
Section III Conclusive Opinions of the Sponsor on the Compliance of the Issuance Process and Issuance Targets...................27
-
Explanation on the compliance of the pricing process for this issuance......................................................27
-
Explanation on the compliance of the selection of targets for this issuance......................................................27
Section IV Conclusive Opinions of the Issuer's Counsel on the Compliance of the Issuance Process and Issuance Targets...........28
Section V Statement of Intermediary Agencies ...............................................................................................29
Section VI Documents Available for Inspection .......................................................................................................34
-
Documents available for inspection......................................................................................................34
-
Inspection locations......................................................................................................34
Definitions
In this Issuance Report, unless the context otherwise requires, the following terms have the following specific meanings: